Drug Discovery World

JUNE 24, 2024

In addition, Insilico is preparing a Phase IIb proof-of-concept study to be initiated in 2025 to explore the efficacy and further safety of INS018_055. The primary objective is to evaluate the safety and tolerability of INS018_055 orally administered for up to 12 weeks in adult subjects with IPF compared to placebo.

Clinical Trials 182

Clinical Trials Trials Disease Treatment 182

Drug Discovery World

JULY 18, 2024

CatalYm is now in preparations to launch further studies in several major cancer indications in combination with checkpoint inhibitors and standard-of-care in first- and second-line treatment in the first half of 2025.

Therapies 130

Therapies Engineering Treatment Regulations 130

Drug Discovery World

JUNE 17, 2024

The roadmap will be formally launched during the Future Labs Live 2025 event at the Congress Centre Basel on Thursday 27 June at 15:45-16:15 (Room Kairo). It is entitled ‘Research roadmap for laboratory community-automating discovery: high throughput experimentation, diagnostics and robotics/AI’.

Laboratories 147

Laboratories Science Research Marketing 147

Drugs.com

MARCH 26, 2024

TUESDAY, March 26, 2025 -- A protein that shuts down immune cells in the lungs could be key to a new treatment for asthma attacks, a new report says.The naturally occurring protein, called Piezo1, prevents a type of immune cell called type 2 innate.

Research 98

Research Treatment 98

Drugs.com

JULY 12, 2024

FRIDAY, July 12, 2025 -- Almost 10% of women who get COVID during pregnancy develop long-lasting symptoms, and a new study suggests doctors may be overlooking them."I I doubt most obstetric clinicians are as aware of Long COVID as perhaps we should.

Doctors 52

Doctors 52

The Pharma Data

MAY 18, 2021

It is anticipated that the combined moves will see over a billion toothpaste tubes per year become recyclable by 2025. We have made the commitment that 100% of our product packaging will be recyclable or reusable, where quality and safety permits, by 2025.This

Packaging 40

Packaging Science Marketing Production 40

Drug Discovery World

NOVEMBER 11, 2022

Subsequently, the companies aim to report emissions data from Phase II and III trials beginning in 2025. . More so, from 2025, the companies will look to include a review of how digital solutions can reduce emissions, with a target of including over 90% of their clinical trials in this review. .

Pharma Companies 239

Pharma Companies Clinical Trials Government Trials 239

Drug Discovery World

JUNE 29, 2023

The investment expands on AstraZeneca’s initial AZ Forest commitment, announced in 2020, to plant and maintain more than 50 million trees by the end of 2025. Planting has progressed in Australia, Indonesia, Ghana, the UK, the US and France, with over 300 tree species.

Science 246

Science Drugs 246

thought leadership

MAY 7, 2024

Are You Ready for Mandatory EU Health Technology Assessment Regulation (HTAR) Implementation Beginning January 2025? Pharmaceutical companies need to be prepared for the new European Health Technology Assessment Regulation (HTAR), which will take effect in January 2025.

Pharmaceutical Companies 59

Pharmaceutical Companies International Regulations Pharmaceuticals 59

Drug Discovery World

FEBRUARY 2, 2024

With the support of our committed and new investors, along with our research collaborations with academic institutions that are in place, we remain on track to deliver a candidate drug for our lead PMS2 programme by early 2025.” The post Financing extension for small molecule neoantigen immuno-oncology company appeared first on Drug Discovery World (..)

Small Molecule 130

Small Molecule DNA Clinical Development Research 130

Drug Discovery World

MAY 23, 2024

ALTB-268 is currently being studied in a Phase IIa exploratory biomarker study in patients with biologic refractory UC with an anticipated readout for its primary endpoint of clinical remission per modified Mayo score in 1H 2025.

Clinical Trials 130

Clinical Trials Trials Clinical Development Treatment 130

BioPharma Drive: Drug Pricing

OCTOBER 4, 2023

The company is planning to start a Phase 3 trial of the vaccine this year, and is targeting a regulatory approval in 2025.

Vaccine 111

Vaccine Trials 111

Science Daily: Pharmacology News

JANUARY 19, 2024

The new insulin is ready to be tested on humans in 2025. The medication that can be taken orally has already been tested on baboons, in which it was found to lower the blood sugar levels without causing hypoglycemia. If all goes well, diabetics are facing an easier life without injections.

Research 94

Research 94

Drug Discovery World

JUNE 4, 2024

billion to local investment by March 2025 and is part of the government’s Levelling Up agenda. Supporting early-stage life science companies The project is being funded by the UK Government through the UK Shared Prosperity Fund, aligning with Bruntwood SciTech’s commitment to driving growth and knowledge sharing in the region.

Science 130

Science Laboratories Government Marketing 130

SCIENMAG: Medicine & Health

MARCH 19, 2024

Credit: IVI IVI will complete the technology transfer by 2025 Oral Cholera Vaccine to be manufactured by Biological E.

Vaccine 82

Vaccine Marketing International 82

thought leadership

JUNE 4, 2024

The HTAR will take effect in January 2025 for oncology and/or advanced therapy medicinal product (ATMP) therapies, with other therapies following a staggered implementation process, including orphan drugs in 2028 and all drugs in 2030.

Therapies 59

Therapies Regulations Production Marketing 59

BioPharma Drive: Drug Pricing

MAY 13, 2024

As commercial momentum builds, coverage incentives for the Medicare market are expected to favor biosimilars in 2025.

Biosimilars 56

Biosimilars Marketing 56

Agency IQ

MARCH 25, 2024

ECHA publishes the 2024 update to CoRAP On March 19, ECHA published the list of CoRAP substances to be evaluated during 2024, 2025 and 2026. Below is the final list, which, when compared to CoRAP for 2023-2025 , encompasses 11 new substances in addition to the 17 substances that were already present on the list (for a total of 28).

Compliance 40

Compliance Production Regulations 40

Agency IQ

MAY 17, 2024

The bill will set a variety of timelines for state regulators to identify industrial uses of PFAS and develop action levels for PFAS in state waters by mid-2025. BY WALKER LIVINGSTON, ESQ On May 9, 2024, Maryland Governor WES MOORE approved the Protecting State Waters From PFAS Pollution Act. Fill out the form to read the full article.

Regulations 59

Regulations 59

Drug Discovery World

DECEMBER 4, 2023

It is hope that the new centre, which is due for completion in summer 2025, will set the stage for a thriving life sciences cluster in the area. The University of Glasgow and Kadans Science Partner, supported by Scottish Enterprise, have announced plans to construct a new Health Innovation Hub in Govan in Glasgow.

Science 130

Science Laboratories Hospitals Research 130

Drug Discovery World

MAY 6, 2024

Building upon findings from our successful Phase II 2 clinical trial, we are working diligently to execute our ongoing Calypso Phase III 3 study and look forward to topline data in 2025.” The post FDA fast tracks Amolyt’s hypoparathyroidism therapy appeared first on Drug Discovery World (DDW).

FDA 130

FDA Therapies Clinical Trials Trials 130

Drug Discovery World

SEPTEMBER 7, 2022

billion at the global headquarters in Darmstadt by 2025. Merck has opened a new Launch and Technology Center for healthcare in Darmstadt, costing the company around €160 million. This is part of a planned investment of more than €1.5

Production 130

Production Research Drugs Pharmaceuticals 130

BioPharma Drive: Drug Pricing

DECEMBER 19, 2023

A decision by European regulators to revoke approvals for five generic versions of Biogen's multiple sclerosis medicine helps cement the drug's monopoly there through early 2025.

Marketing 64

Marketing Regulations Drugs 64

Drugs.com

APRIL 12, 2024

FRIDAY, April 12, 2025 -- Young women who find a lump or other potential signs of breast cancer often delay for weeks before finally seeing a doctor, a new study shows.On average, young women waited two weeks before seeing a doctor about troubling.

Doctors 52

Doctors 52

Drug Discovery World

APRIL 5, 2024

Worsening Heart Failure The clinical course of heart failure is characterised by periods of clinical stability being frequently interrupted by episodes of worsening symptoms and signs, defined as Worsening Heart Failure.

Treatment 130

Treatment Pharmaceuticals Therapies Trials 130

Agency IQ

MARCH 7, 2024

BY AMANDA CONTI Yesterday, FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) weighed in on strains for seasonal influenza vaccines for the Northern hemisphere 2024-2025 season. The meeting was straightforward, since both industry and FDA are ready ahead of schedule to remove one out-of-circulation influenza strain.

Vaccine 59

Vaccine FDA Production 59

Drug Discovery World

OCTOBER 25, 2023

The Phase Ib trial is expected to read out in the second half of 2025. The second, dose-expansion, phase of the study (Phase Ib) is to further evaluate the safety, pharmacokinetics / pharmacodynamics, and efficacy of IKS014 at the recommended Phase II dose. The study is currently enrolling patients at five planned locations in Australia.

Pharmacokinetics 130

Pharmacokinetics Trials Drugs Clinical Trials 130

Drug Discovery World

MAY 8, 2024

The company is conducting additional clinical trials with setanaxib and will read out its Phase II trial in PBC (primary biliary cholangitis) in Q3 of 2024 and is expecting the investigator led Phase II trial in IPF (idiopathic pulmonary fibrosis) to provide top line data in Q4 of 2024, subject to recruitment.

Trials 173

Trials Clinical Trials Treatment Disease 173

Drug Discovery World

OCTOBER 21, 2022

Zanidatamab has the potential to deliver significant long-term value and meaningfully contribute to Vision 2025 as we aim to deliver at least five novel therapies to patients by the end of the decade.”. The post Jazz acquires rights to HER2-targeted bispecific antibody appeared first on Drug Discovery World (DDW).

Licensing 130

Licensing Licensing Treatment Pharmaceuticals 130

Drug Discovery World

MAY 15, 2024

The vaccine should enter Phase I clinical trials in early 2025, but its complex nature makes it challenging to manufacture which could limit large-scale production. Diana Spencer, Senior Digital Content Editor, DDW The post ‘Proactive’ vaccine can protect against unknown future coronaviruses appeared first on Drug Discovery World (DDW).

Vaccine 130

Vaccine Immune Response Clinical Trials Virus 130

Drug Discovery World

MAY 25, 2023

Apexigen’s sotigalimab is a potential best-in-class Phase II CD40 agonist, that has demonstrated rapid, deep and durable responses across difficult-to-treat tumour types.

Clinical Trials 130

Clinical Trials Trials Drugs 130

Drug Discovery World

JANUARY 23, 2024

Ultimately, the clinical development industry is beginning to recover from the pandemic, but we can expect the long-term impact to stretch into 2025,” commented Dr Li. “To To minimise the impact of disruption, there is a growing need for trial design and execution to become more data-led.

Disease 130

Disease Research Clinical Trials Trials 130

DS in Pharmatics

JANUARY 2, 2024

billion by 2025.[2] Biotechnology firms are cropping up all over the place, and growing at an unbelievable rate. California alone is home to over 3,000 life sciences companies, employing over 287,000 people[1] and the global industry is expected to be worth $727.1

Science 52

Science 52

Agency IQ

JANUARY 12, 2024

To kick off 2024, the British device regulator offered its medical device and IVD plans for this year and next, promising public action on the post-market surveillance regulation by mid-2024 and on the core regulations in late 2024 or early 2025. has done.

Regulations 59

Regulations Marketing 59

Drug Discovery World

FEBRUARY 22, 2023

The company plans to initiate the infant Phase II study in the second quarter of 2023, with topline safety, tolerability and immunogenicity data following the primary three-dose immunisation series expected by 2025.

Vaccine 130

Vaccine Trials FDA Disease 130

BioPharma Drive: Drug Pricing

SEPTEMBER 28, 2023

The test developer will use the Series B funding to complete a 10,000-person clinical trial ahead of a planned launch in 2025.

Clinical Trials 60

Clinical Trials Trials 60

Drug Discovery World

JUNE 12, 2023

Patient recruitment is expected to start by the end of Q2 2023 with results anticipated by late 2025. The US Food and Drug Administration (FDA) has approved Minoryx Therapeutics’ Phase III clinical trial (CALYX) of leriglitazone, to treat adult male X-linked Adrenoleukodystrophy (X-ALD) patients with cerebral Adrenoleukodystrophy (cALD).

FDA Approval 130

FDA Approval FDA Trials Clinical Trials 130